Ozmosi | Trotabresib Drug Profile

Product Description

Trotabresib is an orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/118021883)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trotabresib

Countries in Clinic: Canada, Japan, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT03936465	NCT03936465	P1	Completed	Lymphoma\|Brain Cancer	2024-03-16		2024-10-03	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
JapicCTI-205272	JapicCTI-205272	P1	Active	Follicular Lymphoma\|Basal Cell Carcinoma\|B-Cell Marginal Zone Lymphoma\|Large Cell Carcinoma\|Diffuse Large B-Cell Lymphoma\|Lymphoma, Non-Hodgkin	2022-12-31

Recent News Events

Date	Type	Title
10/12/2023	News Article	Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
06/02/2023	PubMed	Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
05/01/2023	PubMed	BRD4: New hope in the battle against glioblastoma.
03/13/2023	PubMed	BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
09/08/2020	News Article	Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Trotabresib

Alternative Names: trotabresib, cc-90010, cc90010, cc 90010 Clinical Status: Active Latest Update: 2024-10-07 Latest Update Note: Clinical Trial Update